KENGREAL™
Clinical pharmacology
| Initial U.S. Approval: 2015
Mechanism of Action: Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation. |
Indications and usage
| INDICATIONS AND USAGE: KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. |
Dosage and administration
| Drug UPDATES: KENGREAL™- cangrelor injection, powder [Drug information / PDF] Click link for the latest monograph Dosing: Click (+) next to Dosage and Administration section (drug info link) |
How supplied
| HOW SUPPLIED: For Injection: 50 mg of KENGREAL lyophilized powder in a single-use 10 mL glass vial for reconstitution. |
Reference
| Drug UPDATES: KENGREAL™- cangrelor injection, powder [Drug information / PDF] Click link for the latest monograph |
Reference(s)
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
